Mercaptamine - NovaBiotics

Drug Profile

Mercaptamine - NovaBiotics

Alternative Names: Cysteamine - NovaBiotics; Lynovex; NM 001 - NovaBiotics; NM-002; Nylexa

Latest Information Update: 13 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NovaBiotics
  • Class Antibacterials; Antidotes; Hepatoprotectants; Mercaptoethylamines; Mucolytics; Small molecules
  • Mechanism of Action Glutathione synthase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Cystic fibrosis-associated respiratory tract infections

Most Recent Events

  • 10 Jul 2018 Efficacy data from the phase IIb CARE-CF1 trial in Cystic fibrosis-associated respiratory tract infections released by NovaBiotics
  • 10 Jul 2018 NovaBiotics plans a phase III trial for Cystic fibrosis-associated respiratory tract infections
  • 01 Apr 2018 NovaBiotics completes a phase II trial in Cystic fibrosis-associated respiratory tract infections (Adjunctive treatment) in Italy, United Kingdom, USA (PO) (NCT03000348)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top